Advances in machine learning for optimizing pharmaceutical drug discovery

Abstract

The integration of advanced machine learning methodologies has revolutionized the field of pharmaceutical drug discovery by addressing critical challenges in efficiency, scalability, and accuracy. This manuscript explores key machine learning paradigms, including deep learning, natural language processing, transfer learning, few-shot learning, and federated learning, highlighting their transformative impact on drug discovery processes. Deep learning architectures, such as convolutional neural networks, recurrent neural networks, and attention-based models, have enabled precise predictions of molecular properties, protein structures, and ligand-target interactions, accelerating lead compound identification and optimization. Natural language processing tools like SciBERT and BioBERT have streamlined biomedical knowledge extraction, uncovering novel drug-disease relationships and facilitating rapid therapeutic advancements during critical scenarios such as the COVID-19 pandemic. Transfer learning and few-shot learning have proven effective in scenarios with limited datasets, leveraging pre-trained models to predict molecular properties, optimize lead compounds, and identify toxicity profiles. Meanwhile, federated learning has enabled secure multi-institutional collaborations, integrating diverse datasets to discover biomarkers, predict drug synergies, and enhance virtual screening without compromising data privacy. These methodologies collectively foster innovation in drug discovery by enhancing precision, reducing development timelines, and lowering costs. By providing an overview of these cutting-edge machine learning approaches and their applications, this review underscores their potential to accelerate pharmaceutical research, optimize therapeutic development, and address complex challenges in the evolving landscape of drug discovery.